Abbvie to submit Genmab-developed cancer drug for EMA approval
According to the Danish firm, the injection cancer drug being developed through Genmab and Abbvie’s oncology partnership, will be on the EMA’s table for evaluation in the second half of 2022.
by marketwire, translated by daniel pedersen
Monday, Genmab announced that partner Abbvie will submit subcutaneous epcoritamab, a treatment for patients with relapsed diffuse large B-cell lymphoma, with the European Medicines Agency (EMA) in the second half of 2022, according to a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Y-mabs enters clinic with new cancer candidate
For subscribers
Roche awarded priority review status for Genmab drug rival
For subscribers
.jpg)
.jpg&w=384&q=75)
